ME
vs
S&P 500


Over the past 12 months, ME has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +13% growth.
Stocks Performance
ME vs S&P 500
Performance Gap
ME vs S&P 500
Performance By Year
ME vs S&P 500
23andMe Holding Co.
Glance View
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
